Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages

Area of Science:

• Molecular Biology
• Cancer Research
• Biochemistry

Background:

• SF3B1 is a core spliceosome component implicated in various cancers.
• SF3B1 is a target for novel cancer therapeutics.
• Mechanistic understanding of SF3B1 function is needed.

Purpose of the Study:

• To investigate the mechanistic role of SF3B1 in pre-mRNA splicing.
• To elucidate the mechanism of action of SF3B1 inhibitor compounds.

Main Methods:

• In vitro splicing assays using SF3B1 inhibitor compounds.
• Analysis of spliceosome assembly and function.
• Competition assays with active and inactive inhibitor analogs.

Main Results:

• SF3B1 inhibitors impact multiple stages of splicing, including exon ligation.
• Structurally distinct inhibitors share a common binding site and mechanism.
• Inhibition likely involves a conformational change in SF3B1.

Conclusions:

• SF3B1 is essential throughout the splicing process.
• SF3B1 inhibitors act via a shared pharmacophore, suggesting a conformational mechanism.
• SF3B1 is a validated target for cancer therapy.